Lowers FY24 revenue view to up 4%-5% from up 4.5%-5.5%. The company said, “The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted1 earnings per share financial guidance.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Signs Definitive Agreement to Acquire OrthoGrid Systems, Inc.
- Zimmer Biomet Announces Second Quarter 2024 Financial Results
- ZBH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Osstem Implant in advanced talks to buy ZimVie, Bloomberg reports
- Zimmer Biomet price target lowered to $117 from $130 at Truist